Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
From Caspase-8 Signals to Caspase-3 Strategy
2026-09-17
A translational framework for converting caspase-8 mechanistic findings into quantitative caspase-3 activity measurement, with strategic guidance for assay selection, validation, and therapeutic interpretation.
Clathrin-Mediated Entry of Grass Carp Reovirus
2026-09-16
Wang et al. combined pharmacological inhibition, transmission electron microscopy, and quantitative PCR to show that genotype III grass carp reovirus enters CIK cells through a clathrin-, dynamin-, and endosome-acidification-dependent pathway. The study also found that Latrunculin B did not block infection under the tested conditions, making the result useful for distinguishing clathrin-mediated uptake from an essential requirement for actin filament assembly.
Lambda Protein Phosphatase for BMAL1 Studies
2026-09-16
Lambda Protein Phosphatase provides a practical dephosphorylation strategy for testing how BMAL1 phosphorylation influences phase-separated transcriptional hubs. This guide connects λ-PPase assay design with antibody validation, phosphorylation site validation, and functional circadian readouts.
Metabolic Stress, DNA Repair, and Repaglinide
2026-09-15
Energy availability is emerging as a controllable variable in genome maintenance. This thought-leadership analysis connects recent AML findings on ATG4B, PRMT1, and MRE11 with a translational strategy for evaluating Repaglinide as a hypothesis-generating metabolic perturbation—not as a validated leukemia therapy.
SFI Inhibits Glioma via SRC/PI3K/AKT Signaling
2026-09-15
The reference study combines network pharmacology with cell-based and mouse experiments to investigate how Shenqi Fuzheng injection suppresses glioma proliferation and migration. Its results identify SRC/PI3K/AKT signaling as a candidate mechanistic axis, while also showing cell-cycle arrest, reduced epithelial–mesenchymal transition markers, and slower tumor growth in a transplanted model.
S1P/S1PR3 Drives Neuronal Apoptosis After ICH
2026-09-14
The reference study identifies an S1P–S1PR3 axis that links acute intracerebral hemorrhage with CCL2 and TNF-α induction, PI3K/AKT-associated signaling, and caspase-3 activation in neurons. Mouse and HT22-cell experiments indicate that pharmacological S1PR3 blockade reduces apoptosis and improves injury-associated outcomes, while also emphasizing the receptor- and tissue-dependent nature of S1P biology.
HNF4A-AS1 Loss Drives Sorafenib Resistance in HCC
2026-09-14
The 2024 Theranostics study identifies liver-enriched lncRNA HNF4A-AS1 as a regulator of sorafenib-induced ferroptosis in hepatocellular carcinoma. Its loss increases DECR1, reduces intracellular polyunsaturated fatty acids, and promotes drug resistance through an METTL3–m6A–YTHDF3 RNA regulatory axis.
Tigecycline and the New MDR Research Playbook
2026-09-13
Tigecycline is more than a broad-spectrum glycylcycline antibiotic: it is a useful translational probe for connecting ribosomal inhibition, resistant-pathogen phenotypes, mobile carbapenemase genes, and clinically relevant infection models. This article outlines a surveillance-informed framework for evaluating its value in multidrug-resistant bacteria research.
Gefitinib Sensitizes Cisplatin-Resistant wtEGFR NSCLC
2026-09-12
This 2020 study identifies increased EGFR phosphorylation as a potential off-target component of Cisplatin resistance in wild-type EGFR non-small cell lung cancer models. It further shows that gefitinib combined with Cisplatin suppresses resistant-cell proliferation, promotes apoptosis, and inhibits H358R xenograft growth more effectively than either treatment alone.
HHV-7 DNA in Refractory Ocular Toxoplasmosis
2026-09-11
Miyase et al. reported the first vitreous-fluid co-detection, to the authors’ knowledge, of Toxoplasma gondii and human herpesvirus 7 DNA in refractory ocular toxoplasmosis. The case suggests that HHV-7 reactivation may contribute to persistent inflammation, while also illustrating why intraocular sampling and multiplex PCR can refine diagnosis when empiric therapy fails.
Lipo3K Transfection Reagent for GBM Studies
2026-09-11
Build reproducible PXDN–LDHA experiments in glioblastoma models with a low-toxicity lipid transfection reagent suited to plasmids, siRNA, and co-transfection workflows. Lipo3K supports difficult cell lines, serum-compatible delivery, and direct collection for downstream molecular and metabolic assays.
Iron Deficiency, KDM4D, and MSC Quiescence
2026-09-10
A 2024 study identifies an iron-sensitive KDM4D–H3K9me3–PIK3R3 mechanism that regulates mesenchymal stem cell activation through PI3K-Akt-Foxo1 signaling. Its findings connect impaired epigenetic regulation under iron deficiency with reduced bone mass and provide a framework for testing pathway-level rescue strategies in osteoporosis research.
Protease and Phosphatase Inhibitor Cocktail Guide
2026-09-10
The Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O) helps limit proteolysis and dephosphorylation during extraction or lysis of cells, tissues, yeast, and bacteria. Its EDTA-free formulation is appropriate when metal chelation is undesirable, but it should not be treated as a universal substitute for assay-specific optimization or as proof of compatibility with every downstream enzyme measurement.
GPC3-HSP70 mRNA Nanovaccine for HCC Immunotherapy
2026-09-09
The reference study develops a GPC3-targeted mRNA nanovaccine that combines repeated GPC3127–136 CTL epitopes with HSP70 and tumor-directed SP94 peptide delivery. In preclinical testing, vaccination increased antigen-specific T-cell activity, while combination with anti-PD-L1 therapy produced stronger antitumor effects than either strategy alone.
FLOT1–FOSL2–EphA2 Axis in Alzheimer’s Disease
2026-09-09
A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in APP/PS1 mice. FLOT1 silencing reduced neuroinflammatory responses and improved spatial memory, supporting this pathway as a mechanistic target for Alzheimer’s disease research while highlighting the need for validation beyond transgenic models.
8160 records 7/544 page Previous Next First page 上5页 678910 下5页 Last page